IPO Analysis Framework: How to Evaluate Whether an IPO Is Worth Your Money — The Complete 10-Point Checklist Every Indian Investor Must Use Before Applying to Any IPO

Why Most Indian Investors Lose Money in IPOs — And How You Can Be Different

India is in the grip of an IPO frenzy. In just the first 55 days of 2026, 31 companies went public across the Mainboard and SME platforms. The IPO pipeline for the rest of the year is worth over ₹2 lakh crore, with marquee names like Reliance Jio Platforms, PhonePe, and Flipkart waiting in the wings.

But here is the uncomfortable truth that nobody on CNBC or social media will tell you: 7 out of 11 mainboard IPOs listed in early 2026 delivered negative listing gains. Average listing gains have crashed from 30% in 2024 to a pathetic 9% in 2025, with further moderation in 2026. In the SME segment, the carnage is even worse — listing gains plummeted from over 60% in 2024 to just 2.63% by early 2026, and 132 out of 254 SME IPOs in 2025 ended the year in losses.

So why do retail investors keep pouring money into IPOs blindly? Because they lack a systematic framework to evaluate whether an IPO deserves their capital. Today, I am going to give you the exact 10-point IPO Analysis Framework that I use before even considering an IPO application. This is the kind of analytical discipline that separates serious value investors from gamblers chasing listing-day pops.

The 10-Point IPO Analysis Framework for Indian Investors

Point 1: Business Model Clarity — Can You Explain It in One Sentence?

Before you even open the Red Herring Prospectus (DRHP), ask yourself: do I understand what this company does? If you cannot explain the business model to a 10-year-old in one sentence, you have no business investing in that IPO. This is not snobbery — it is survival. Warren Buffett famously said, “Never invest in a business you cannot understand.”

When Titan Biotech (BSE: 524717, CMP: ₹529, Market Cap: ₹2,187 Cr) was a small, unknown company years ago, its business model was crystal clear — manufacturing and exporting biological products like peptones, culture media, and agar used in pharma, diagnostics, and food testing. You could explain it in one line. That clarity of purpose is what allowed patient investors to hold through its entire journey to becoming a multibagger. Today, with ROCE of 16.9% and ROE of 15.0%, Titan Biotech continues to demonstrate the power of backing businesses you truly understand.

Too many IPO investors get seduced by buzzwords like “AI-driven,” “platform play,” or “disruptive ecosystem.” If the company cannot show you a clear, profitable business model — walk away.

Point 2: Promoter Quality and Skin in the Game

The single biggest predictor of an IPO’s long-term success is the quality and integrity of the promoter. Here is what to check:

Promoter holding post-IPO: Is the promoter retaining a significant stake (ideally 50%+), or are they using the IPO as an exit vehicle? If the IPO is predominantly an Offer for Sale (OFS) — meaning existing shareholders are selling their shares to you — that is a massive red flag. It means the people who know the business best want OUT. Why would you want IN?

Promoter track record: Has the promoter built and run successful businesses before? Check their LinkedIn, their previous ventures, any legal proceedings against them. SEBI’s new disclosure norms require detailed promoter backgrounds in the DRHP — read every word of it.

Salary and perks: If the promoter is paying themselves ₹10-15 crore in salary while the company earns ₹20 crore in profit, that tells you everything about their priorities. The best promoters are frugal operators who treat shareholder capital as sacred.

Point 3: The OFS vs Fresh Issue Split — Follow the Money

This is perhaps the most overlooked red flag in IPO analysis. Every IPO has two components: Fresh Issue (new shares issued by the company, money goes INTO the company) and Offer for Sale (existing shares sold by promoters/investors, money goes INTO their pockets).

A healthy IPO has a dominant Fresh Issue component, where the company is raising capital for genuine growth — capex, R&D, debt repayment, working capital. When the OFS component dominates, it means private equity funds and early investors are cashing out at premium valuations, and you are funding their exit.

Real example: Many of the 2024-2025 IPOs that crashed after listing had 60-80% OFS components. The promoters and PE investors laughed all the way to the bank while retail investors were left holding expensive shares with no growth capital injected into the company.

Point 4: Valuation Sanity Check — The P/E Trap

IPO pricing in India has become increasingly aggressive. Investment bankers price IPOs at the maximum the market will bear, not at fair value. Your job as an investor is to ask: am I paying a fair price for this business, or am I paying for 5 years of growth upfront?

Here is a simple framework:

First, look at the IPO P/E ratio (price-to-earnings). Compare it with listed peers in the same sector. If the IPO is priced at a P/E of 50x while listed peers trade at 25x, you are paying a 100% premium for an unproven public track record. Second, look at the Price-to-Sales ratio for loss-making companies. If the company has no profits, a P/S above 10x is almost always dangerous. Third, calculate the EV/EBITDA and compare with industry averages. This is more reliable than P/E for capital-intensive businesses.

Remember — in the current market environment, with Nifty 50 at 22,968 and Sensex around 74,000 levels (as of April 6, 2026), valuations across the board are elevated. This makes IPO evaluation even more critical.

Point 5: Use of IPO Proceeds — Where Is Your Money Going?

The DRHP contains a detailed section on how the company plans to use the IPO proceeds. This is not a boring legal section — it is the entire investment thesis. Read it carefully.

Green flags: Capital expenditure for new manufacturing plants, R&D investment, repayment of high-cost debt, funding working capital for proven order books.

Red flags: Vague language like “general corporate purposes” consuming 30-40% of proceeds, excessive spending on “brand building” or “inorganic growth” without specific targets, repayment of loans taken from promoter group entities (circular transactions).

The best IPOs are those where every rupee raised has a clear, quantifiable deployment plan with projected ROI. If the company cannot tell you exactly what they will do with your money, they do not deserve it.

Point 6: Financial Track Record — Three-Year Trend Analysis

SEBI requires companies to disclose three years of audited financials in the DRHP. Here is what to analyze:

Revenue growth trajectory: Is revenue growing consistently at 15%+ CAGR, or is it lumpy and volatile? Consistent growth indicates a sustainable business model. Lumpy revenue suggests cyclicality or dependence on one-off orders.

Profitability trend: Are operating margins expanding, stable, or contracting? Expanding margins (like Titan Biotech’s operating margin growth from 10% to 19% over the years) indicate pricing power and operational efficiency. Contracting margins are a death sentence for growth stories.

Cash flow quality: Is the company generating positive operating cash flow? Many IPO companies show impressive profits on paper but burn cash like wildfire. If operating cash flow is consistently negative despite reported profits, something is wrong.

Return ratios: ROCE above 15% and ROE above 12% are minimum thresholds for a quality business. These indicate the company can generate returns above its cost of capital.

Point 7: Competitive Moat — What Stops Competitors?

One question cuts through all the noise: if a well-funded competitor entered this market tomorrow, could they easily replicate what this company does?

Genuine moats include regulatory licenses and approvals (pharma, defense), proprietary technology or patents, network effects (marketplace businesses), switching costs (enterprise software), cost advantages from scale, and strong brand recognition built over decades.

Most IPO companies claim to have moats. Very few actually do. Be ruthlessly skeptical. A company going public at a ₹5,000 crore valuation that can be disrupted by a startup with ₹50 crore in venture funding has no moat.

Point 8: Grey Market Premium (GMP) — The Noise to Ignore

Here is a contrarian take that will upset the “IPO listing gains” crowd: Grey Market Premium is completely irrelevant to value investors.

GMP is an unofficial, unregulated indicator driven by speculation, operator manipulation, and short-term sentiment. It tells you absolutely nothing about the long-term value of a business. Some of the biggest IPO disasters of 2024-2025 had massive GMPs before listing, only to crash 40-50% within six months.

If your IPO investment thesis is based on GMP, you are not an investor — you are a gambler. And as SEBI’s own study confirms, 9 out of 10 individual traders in the equity F&O segment incurred net losses. Chasing short-term IPO listing gains is just F&O gambling with a different name.

Point 9: Lock-in Period and Anchor Investor Analysis

After listing, anchor investors have a mandatory lock-in period (now 90 days under SEBI’s new norms for 50% of the allocation). When this lock-in expires, a flood of selling can crash the stock price. This is called the “lock-in expiry dump.”

Smart investors track these dates and sometimes find better entry points 3-6 months after listing when the initial hype dies down and anchor investors exit. Some of the greatest value investments were made by buying quality IPO companies at 30-40% below their listing price, after the institutional selling exhausted itself.

SEBI has tightened anchor investor norms significantly in late 2025 — stricter allocation rules, enhanced disclosures, and revised pricing mechanisms. These changes are making the IPO process more transparent, but they also mean that easy listing-day money is becoming increasingly rare.

Point 10: The “Would I Hold This for 10 Years?” Test

This is the ultimate filter. After all your analysis, ask yourself one final question: if this stock were to get delisted tomorrow and I could not sell it for 10 years, would I still buy it at this IPO price?

If the answer is no, you should not apply for the IPO — period. This test eliminates all the noise about listing gains, GMP, oversubscription ratios, and short-term momentum. It forces you to think like a business owner, not a trader.

Think about it this way: when Titan Biotech was a small, illiquid stock, the investors who profited the most were those who treated it as a long-term business ownership stake, not a trading ticket. They analyzed the fundamentals — consistent revenue growth, expanding margins, high ROCE (16.9%), debt-free balance sheet — and then simply held. That is the mindset you need for IPO investing too.

Why I Almost Never Apply for IPOs — And You Should Think Twice Too

Here is my honest confession: I rarely apply for IPOs. Not because all IPOs are bad — some genuinely great companies come to market — but because the odds are stacked against retail investors in the IPO process.

Investment bankers price IPOs to maximize proceeds for the issuer, not to leave value on the table for you. Institutional investors get 75% of the allocation through QIB quotas and often at better terms. Retail investors get the smallest slice (35% in mainboard IPOs) at the highest price. And the information asymmetry is enormous — the promoters and merchant bankers know everything about the business while you are reading a 500-page DRHP for the first time.

This is why the concentrated approach to investing is so powerful. Instead of spreading your capital across 10 IPOs hoping for listing gains, why not focus that same capital on 5-8 deeply researched quality businesses that are already listed, already have a proven track record, and are available at reasonable valuations? As Warren Buffett wisely said, “Wide diversification is only required when investors do not understand what they are doing.”

The greatest wealth in Indian stock markets has been created not by IPO flipping, but by identifying quality businesses early and holding them with conviction for years. That is the philosophy we teach at Multibagger Shares, and it is the philosophy that has created more millionaire investors than any IPO subscription ever will.

SEBI’s Evolving IPO Regulations — What You Must Know in 2026

These regulations are designed to curb the speculative frenzy that had gripped the SME IPO market, where companies with questionable fundamentals were getting 100x+ oversubscribed purely on hype. The message from SEBI is clear: the era of blind IPO gambling is ending. Only companies with genuine fundamentals and transparent governance will survive the new regulatory environment.

The Bottom Line: Your IPO Homework Checklist

Before you apply for any IPO, run through this 10-point framework: (1) Can you explain the business model in one sentence? (2) Are the promoters retaining significant skin in the game? (3) Is the fresh issue component dominant over OFS? (4) Is the valuation reasonable compared to listed peers? (5) Is the use of proceeds clearly defined with measurable goals? (6) Does the 3-year financial track record show consistent growth? (7) Does the company have a genuine competitive moat? (8) Are you ignoring GMP and focusing on fundamentals? (9) Have you checked anchor investor lock-in expiry dates? (10) Would you hold this stock for 10 years at the IPO price?

If a company passes all 10 tests, it might — and I emphasize might — be worth your capital. If it fails even 2-3 of these tests, move on. There are over 5,000 listed companies on BSE and NSE. You do not need to chase IPOs to build wealth.

To deepen your understanding of value investing frameworks like this one, check out our comprehensive Value Investing Course: Value Investing Course Playlist.

Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.

Manish Goel

Manish Goel is a long-term value investor and the founder of Manish Goel Stocks, where he publishes daily, plain-English lessons on fundamental analysis for Indian investors. His writing focuses on reading annual reports, decoding financial ratios, spotting red flags, and building the patience and discipline that compounding rewards. Every article here is educational — never a buy or sell call — and free to read.

See Full Bio